Ivan van Rooyen. (Getty Images) Ivan 'Cash' van Rooyen is the son-in-law of the late Springbok centre Darius Botha.His outlook on 'resetting' his tenure at the Lions is based on his father-in-law's glass half-full philosophy. A self-confessed team man, Van Rooyen believes the Lions can apply many lessons from their relegation from Super Rugby in 2012…
Renowned coach and tennis analyst Brad Gilbert believes former world No 1 Roger Federer will struggle to get his mojo back after the coronavirus-enforced break from professional tennis.Unseeded, struggling to get his "mojo back" and the fact that he will be 39-years-old are just some of the things that "could mean trouble" for Roger Federer…
Bafana Bafana 2020-05-20 15:55 Dean Furman (Gallo Images) Bafana Bafana coach Molefi Ntseki has lauded Dean Furman while former SuperSport United defender Thabo September says the player will be missed.Matsatsantsa announced Furman's official departure from the Premier Soccer League club after five years on Tuesday.The South Africa international is currently in England awaiting the birth…
Rito Hlungwani (forwards coach), John Dobson (head coach) and Labeeb Levy (skills coach and performance analyst) during a Stormers training session (Gallo Images) The Stormers have kept their skills sharp during South Africa's Covid-19 lockdown period.Register your interest for the British & Irish Lions tickets in South Africa 2021The Cape franchise’s skills coach Labeeb Levy…
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f